deucravacitinib
bms
['lupus', 'deucra']
#acr22 in people with active #lupus, the trial drug deucravacitinib demonstrated to be effective, safe and well-tolerated. study participants taking the oral therapy saw improvements in disease activity. the study met primary endpoints and moves to phase 3 trial.
Lupus Foundation of America is the only national force devoted to solving the mystery of lupus while giving support to those who suffer from its brutal impact.